In a case study reported in 2021, the ALK- and ROS1-inhibitor lorlatinib was reported successful in treating a patient with refractory TFG-ROS1 fusion-positive IMT (Carcamo et al., 2021). This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.